secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0000929638-25-002215
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve 2025 Employee Stock Purchase Plan; directors elected
-------------------------------------------------------------------------

- Shareholders approved the 2025 ESPP reserving 2,000,000 common shares for issuance.
- Directors Gerald Brunk and Dr. Richard Glickman were elected with 30.5M and 26.3M for votes respectively.
- ESPP effective June 10, 2025, allows eligible employees to purchase shares via payroll deductions.
- Auditor appointment ratified with 38,101,229 votes in favor.
- ESPP intended to qualify under Code Section 423; 74.6% of outstanding shares voted at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000092963825002215/0000929638-25-002215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000092963825002215/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-25-002215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer